8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Oct 14, 2005)

Filed October 14, 2005For Securities:ABT

Summary

Abbott Laboratories (ABT) announced on October 13, 2005, that it received a "not-approvable" letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Xinlay™ (atrasentan). This investigational drug was being considered for patients with metastatic hormone-refractory prostate cancer (HRPC). The FDA's decision follows a recommendation against approval by the Oncologic Drugs Advisory Committee (ODAC) in September. While this news represents a setback for the company's prostate cancer drug pipeline, it is important to note that the FDA's decision specifically pertains to the metastatic HRPC indication. Abbott's ongoing trial M00-244, which is evaluating Xinlay™ in patients with non-metastatic HRPC, will not be affected by this particular outcome. Investors should monitor future developments related to the non-metastatic trial and Abbott's overall drug development strategy.

Key Highlights

  • 1Abbott received a "not-approvable" letter from the FDA for its Xinlay™ (atrasentan) New Drug Application (NDA).
  • 2The intended use for the rejected NDA was for patients with metastatic hormone-refractory prostate cancer (HRPC).
  • 3The FDA's decision aligns with the Oncologic Drugs Advisory Committee's (ODAC) September recommendation against approval.
  • 4This FDA decision does not impact the ongoing clinical trial M00-244, which is studying Xinlay™ in non-metastatic HRPC.
  • 5The filing is made under Regulation FD Disclosure (Item 7.01), meaning the information is furnished and not formally filed with the SEC.
  • 6The information is not intended to be a determination or admission by Abbott regarding materiality for investment decisions.

Frequently Asked Questions

The "not-approvable" letter means that the FDA has determined that it cannot approve the New Drug Application (NDA) for Xinlay™ (atrasentan) in its current form for the treatment of metastatic hormone-refractory prostate cancer (HRPC). This is a significant setback for the drug's approval in this specific indication.

No, the FDA's decision specifically addresses the NDA for metastatic hormone-refractory prostate cancer. Abbott's ongoing clinical trial M00-244, which is evaluating Xinlay™ in patients with non-metastatic hormone-refractory prostate cancer, is not affected by this particular outcome.

The FDA's decision follows a recommendation from its Oncologic Drugs Advisory Committee (ODAC) in September, which did not recommend approval for Xinlay™ for the specified indication. The "not-approvable" letter formalizes the FDA's stance based on the committee's review and likely other factors assessed during the NDA review process.

No, this information is being furnished under Regulation FD Disclosure (Item 7.01). This means it is provided to the public to ensure fair disclosure, but it is not considered formally "filed" with the SEC in the same way as other sections of an 8-K. It is not automatically incorporated into future SEC filings unless explicitly stated by Abbott.